Listed

Nephros Inc: Form 10-K for the period ended Dec 31, 2013

Filed with the SEC on Mar 28, 2014 and accepted by EDGAR at Mar 28, 2014, 14:29 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2013-01-01 to 2013-12-31$1.7mus-gaap:SalesRevenueNet
Cost of revenue12 months2013-01-01 to 2013-12-31$898.0kus-gaap:CostOfGoodsSold
Gross profit12 months2013-01-01 to 2013-12-31$842.0kus-gaap:GrossProfit
Selling, general and administrative12 months2013-01-01 to 2013-12-31$3.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2013-01-01 to 2013-12-31−$3.3mus-gaap:OperatingIncomeLoss
Interest expense12 months2013-01-01 to 2013-12-31$94.0kus-gaap:InterestExpense
Net income12 months2013-01-01 to 2013-12-31−$3.7mus-gaap:NetIncomeLoss
Operating cash flow12 months2013-01-01 to 2013-12-31−$3.6mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure12 months2013-01-01 to 2013-12-31$0us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2013-12-31$579.0kus-gaap:Cash
Current assetsAt period end2013-12-31$988.0kus-gaap:AssetsCurrent
Total assetsAt period end2013-12-31$2.9mus-gaap:Assets
Current liabilitiesAt period end2013-12-31$3.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-12-31$3.5mus-gaap:Liabilities
Shareholders' equityAt period end2013-12-31−$610.0kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-14-018633. Last ingested by Listed: Nov 13, 2026, 16:20 ET. Listed shows no prices and gives no investment advice.